

\*\*\*\*Updated October 2011\*\*\*\*

## EpibaseID™: Global Epidemiology Database (CAT: VAVS020)

<b>Proposal No/#PO</b>	:	<b>[Enter client specific #PO]</b>
<b>Product Name</b>	:	EpibaseID™: Global Epidemiology database for Infectious Diseases
<b>Project Initiation Date</b>	:	n/a
<b>Billable days</b>	:	n/a
<b>Initiator(s)</b>	:	[Enter client name, function and address]
<b>Therapeutic Area</b>	:	n/a
<b>Product (if applicable)</b>	:	<b>CAT No:</b> VAVS020, updated September 2011

### Background

Accurate monitoring of infectious diseases is critical to human health both on the individual and societal level. As long ago as the late 19<sup>th</sup> century in the US, congress authorized the overseas collection of reports detailing the morbidity of various diseases such as cholera, smallpox, plague, yellow fever in order to prevent their introduction and spread into the continental United States. Since 1961 the US Centres For Disease Control and Prevention (CDC) has been responsible for measuring and dissemination of data regarding diseases which are termed “nationally notifiable”. As of 2011, around 65-70 diseases are nationally notifiable in the US ranging the commonly known such as hepatitis (A,B & C), measles and syphilis, to the more obscure causative pathogens of spotted fever rickettsiosis and various viral hemorrhagic fevers. Requirements for reporting diseases are laid down within state laws or regulations although this can vary from year to year and state to state.

In other major Western countries bodies such as the Health Protection Agency (UK), Robert Koch Institute (Germany) and Institut De Veille Sanitaire (INVS, France) are responsible for the collection and dissemination of epidemiological data. On a continental or global level the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation also play an important role.

Because epidemiological data is spread over numerous locations keeping an accurate picture for assessment purposes can be extremely labour intensive and time consuming often requiring the deployment of skilled personnel for long periods. In order to overcome this challenge **VacZine Analytics** has created **EpibaseID™** – a new “on-line” epidemiological database containing around **3000** individual records of disease incidence, prevalence and mortality of over **100** pathogens/indications often down to the sub-species level.

In addition to data from standard major Western economies, the database includes records from the increasingly important emerging market block (BRIC-MTK<sup>1</sup>) and Africa (incl subregions).

## Database Contents

**VacZine Analytics** has meticulously gathered all major epidemiological information within the public domain regarding infectious disease pathogens and related indications (**Table I**) both notifiable and non-notifiable at the national/regional level for the following countries:

United States	Germany	Australia	India	Africa <sup>2</sup>
Canada	Italy	Korea	China	PAHO <sup>3</sup>
United Kingdom	Spain	Brazil	Mexico	WPR
France	Japan	Russia	Turkey	SEA
Other EU <sup>4</sup>				

For each pathogen indication the following fields are included:

**Region** – specifies which region block the data pertains to

**Country** – specifies which country the data pertains to

**Sub area** – specifies which sub area the data pertains to e.g. city, county

**Data type** – specifies whether data is INCIDENCE/PREVALENCE/MORTALITY/CFR

**Incidence** – gives number of reported cases or cases per 100,000 inhabitants where available

**Prevalence** – gives reported prevalence in %, or person living with disease

**Mortality** – gives number or reported deaths, or deaths per 100,000 inhabitants where available, or % case fatality rate

**Incidence (source)** – gives exact source of data, year and website link

**Incidence (detail)** – gives any further details regarding study, sample no, risk groups, age groups, gender, ranges

**Prevalence (source)** – gives exact source of data, year and website link

**Prevalence (detail)** – gives any further details regarding study, sample no, risk groups, age groups, gender, ranges

**Mortality (source)** – gives exact source of data, year and website link

**Mortality (detail)** – gives any further details regarding study, sample no, risk groups, age groups, gender, ranges

<sup>1</sup> Brazil, Russia, India, China, Mexico, Turkey and Korea (South)

<sup>2</sup> Mostly defined to the country level

<sup>3</sup> PAHO = Pan American Health Organisation, WPR = Western Pacific Region and SEA = South East Asia Region

<sup>4</sup> Other EU = 20 EU countries outside major 5 economies

The following pathogens (including relevant subspecies) and indications are included in the database (**Table I**):

<i>Abiotropha</i> spp.	Cytomegalovirus (CMV)	<i>Mycobacterium</i> (leprosy)	<i>Trichomoniasis</i>
<i>Acinetobacter</i> spp.	Dengue fever	<i>N meningitidis</i> (all)	<i>Trichinellosis</i>
Adenovirus	Ebola/Marburg	Non-pyogenic streptococci (all)	Tuberculosis (all forms)
<i>Aerococcus</i> spp.	Echovirus	Onchocerciasis	Tularemia
AIDS/HIV	<i>Ehrlichia chaffeensis</i>	Ornithosis	Viral hemorrhagic fever
<i>Aspergillosis</i> (invasive)	<i>Enchinococcosis</i>	<i>Pediococcus</i> spp.	Varicella Zoster Virus
Astrovirus	<i>Entamoeba histolytica</i>	<i>Peptostreptococcus</i> spp.	West Nile Virus
<i>Anaplasma phagocytophilum</i>	<i>Enterobacter</i> spp. (total)	Poliomyelitis	Yellow Fever
Anthrax	Enterovirus	<i>Pseudomonas</i> spp.	<i>Yersinia</i> spp. (plague)
Amoebiasis	<i>Escherichia coli</i>	Psittacosis	
Arbovirus spp.	<i>Flavimonas</i> spp. (total)	Q fever	
Ascaris	<i>Gardia lamblia</i>	Rabies	
Barmah Forest infection	<i>Gemella</i> spp.	<i>Ralstonia</i> spp.	
<i>Bordetella pertusis</i>	<i>Globicatella sanguis</i>	Respiratory syncytial virus (RSV)	
<i>Brevibacterium</i> spp.	Gonorrhoea	Rotavirus	
Brucellosis	Group A, B, C, G <i>Streptococcus</i>	Rubella (German measles)	
<i>Burkholderia</i> spp.	<i>Haemophilus</i> spp.	SARS	
Caliciv-Norovirus	Hansen disease	Scabies	
<i>Campylobacteriosis</i>	Hantavirus	Schistosomiasis	
<i>Candida albicans</i>	Hepatitis A,B,C,D,E	Scrub typhus	
Chagas disease	Herpes Simplex Virus	<i>Staphylococcus</i> spp.	
Cholera	Human Papilloma Virus	<i>Salmonella</i> (all types)	
Coxsackievirus spp.	Human parechovirus	<i>Salmonella</i> (excl typhi and paratyphi)	
Chikungunya virus	Influenza virus (seasonal)	Sapovirus	
<i>Chlamydia psittaci</i>	<i>Klebsiella</i> spp.	<i>Serratia</i> spp.	
<i>Chlamydia trachomatis</i>	Legionellosis	<i>Shewanella</i> spp.	
<i>Citrobacter</i> spp.	Leishmaniasis	<i>Shigella</i> spp.	
<i>Clostridia</i> spp. (incl tetani)	Leptospirosis	<i>Sphingomonas</i> spp. (total)	
<i>Comamonas</i> spp.	<i>Leuconostoc</i> spp.	<i>Streptococcus pneumoniae</i> (IPD)	
<i>Corynebacteria</i> (non toxigenic)	<i>Listeria monocytogenes</i>	Syphilis ( <i>Treponema pallidum</i> )	
<i>Corynebacteria</i> (toxigenic)	Lyme borreliosis	Teniasis (tape worm)	
Cryptosporidiosis	Malaria (plasmodium)	Tick-borne encephalitis	
	Measles (Rubeola)	Toxoplasmosis	
	Mumps		

## Methodology

Due to the proprietary nature of the database interested parties should request a separate database methodology worksheet from **VacZine Analytics** directly.

## Deliverables

**EpibaseID™** is an “on-line” version with higher search functionality and capability for continuous updating. Subscribers are given individual usernames/passwords according to **TERMS** and **CONDITIONS**.

## Product Cost

\*\*\*\*Price on application only\*\*\*\*


Interested parties should contact **VacZine Analytics** directly. Pricing is dependent on:

- Type of organisation e.g. Commercial, not-for-profit, individual
- Number of users
- Region of use e.g. North America, EU and Rest of World
- Access to “on-line” version
- Other client requests
- Existing subscriptions to other **VacZine Analytics** products/services

For orders in the UK, VAT at 20% will be added to final invoice total

### HOW TO ORDER:

To order please contact your region account manager or order direct at [info@vaczine-analytics.com](mailto:info@vaczine-analytics.com)  
This report can also be purchased on-line. Please review the **TERMS** and **CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

## TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

### VacZine Analytics

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009